Advanced search
Start date
Betweenand


VASP and Zyxin expression and participation in hematopoietic differentiation, in chronic myeloid leukemia and BCR-ABL signaling pathway

Full text
Author(s):
Vanessa Aline Bernusso
Total Authors: 1
Document type: Master's Dissertation
Press: Campinas, SP.
Institution: Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas
Defense date:
Examining board members:
Karin Spat Albino Barcellos Silveira; Mariana Lazarini; João Gustavo Pessini Amarante Mendes
Advisor: Sara Teresinha Olalla Saad; Karin Spat Albino Barcellos Silveira
Abstract

VASP (vasodilator-stimulated phosphoprotein) and Zyxin are actin regulatory proteins that control cell-cell adhesion. Zyxin directs actin assembly by interacting and recruiting VASP to specific sites of adhesion. The phosphorylation of VASP and Zyxin modifies their activity in cell-cell junctions. PKA phosphorylates VASP at serine 157 regulating VASP cellular functions. VASP interacts with ABL and VASP is a substrate of BCR-ABL oncoprotein. The presence of BCR-ABL protein drives oncogenesis in patients with chronic myeloid leukemia (CML) due to a constitutive activation of tyrosine kinase activity. It has been described an altered expression of VASP and Zyxin in different types of tumor; however the function of VASP and Zyxin in CML, in BCR-ABL pathway and in hematopoiesis remains unknown. We describe here the absence of p-VASP ser157 in CML bone marrow cells, in contrast to p-VASP ser157 expression in healthy donors. Patients responsive to tyrosine kinase inhibitors present p-VASP ser157, while resistant patients do not have p-VASP ser157. In K562 cells we observed that VASP and Zyxin modulate anti-apoptotic proteins BCL-2 and BCL-XL. VASP depletion in K562 cells decreases FAK y925 activity and VASP interacts with FAK. Expression of VASP, p-VASP, Zyxin and p-Zyxin increases during megakaryocyte differentiation and VASP inhibition affects this differentiation through reduced CD61 expression in VASP depleted cells. We identify here the participation of VASP and Zyxin in BCR-ABL pathway affecting anti-apoptotic proteins and, also, in megakaryocyte differentiation. Then, the altered expression of VASP activity in CML patients may contribute to CML pathogenesis, affecting cellular differentiation or leukemic cell adhesion (AU)

FAPESP's process: 11/14498-5 - VASP AND ZYXIN EXPRESSION AND PARTICIPATION IN HEMATOPOIETIC DIFFERENTIATION, IN CHRONIC MYELOID LEUKEMIA AND BCR-ABL SIGNALING PATHWAY
Grantee:Vanessa Aline Bernusso
Support Opportunities: Scholarships in Brazil - Master